Featured Research

from universities, journals, and other organizations

Clozapine Effective For Controlling Dyskinesias In People With Severe Parkinson's

Date:
February 13, 2004
Source:
American Academy Of Neurology
Summary:
Low-dose clozapine is effective in treating dyskinesias (involuntary, often jerky movements) resulting from long-term levodopa therapy in patients with severe Parkinson's disease, according to a study in the February 10 issue of Neurology, the scientific journal of the American Academy of Neurology.

ST. PAUL, Minn. – Low-dose clozapine is effective in treating dyskinesias (involuntary, often jerky movements) resulting from long-term levodopa therapy in patients with severe Parkinson's disease, according to a study in the February 10 issue of Neurology, the scientific journal of the American Academy of Neurology.

Fifty patients participated in the 10-week, double-blind (where neither patients nor research staff know which participants are receiving the experimental treatment or a placebo) clinical trial performed at five hospitals in France. The patients performed self-evaluations of their motor performance fluctuations every two weeks, by means of a diary where they noted duration and intensity of dyskinesias.

Doses of clozapine (an antipsychotic drug used in managing schizophrenia) averaged 39.4 mg/day. Clozapine was taken once daily in the evening.

"Dyskinesias are normally very difficult to treat and pose a serious side effect of levodopa therapy, the most common treatment for Parkinson's patients," according to lead study author Franck Durif, MD, at the Hopital Gabriel Montpied in Clermont-Ferrand. "Our study supports previous preliminary findings that low dose clozapine can reduce dyskinesias by around 50 percent in some patients."

Levodopa-induced dyskinesias (LIDs) are thought to result from increased transmission of dopamine in the brain. Clozapine may be able to mitigate the transmission of toxically high levels of levodopa and thereby reduce its potency and lesson the severity and duration of LIDs, according to the study. "Overstimulation of D1 dopaminergic receptors is believed to be one of the most important mechanisms underlying LIDs in Parkinson's disease," according to Durif.

The study was supported by a grant from the French Ministry of Health.

###

The American Academy of Neurology, an association of more than 19,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, autism and multiple sclerosis.

For more information about the American Academy of Neurology, visit its web site at http://www.aan.com.


Story Source:

The above story is based on materials provided by American Academy Of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy Of Neurology. "Clozapine Effective For Controlling Dyskinesias In People With Severe Parkinson's." ScienceDaily. ScienceDaily, 13 February 2004. <www.sciencedaily.com/releases/2004/02/040212084412.htm>.
American Academy Of Neurology. (2004, February 13). Clozapine Effective For Controlling Dyskinesias In People With Severe Parkinson's. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2004/02/040212084412.htm
American Academy Of Neurology. "Clozapine Effective For Controlling Dyskinesias In People With Severe Parkinson's." ScienceDaily. www.sciencedaily.com/releases/2004/02/040212084412.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins